Although we observed an increase in inflammatory, anti-tumor myeloid cells, we also noted an increase in M-MDSCs in the B16 model after combined treatment with ADU-S100 and either anti-PD-L1 or anti-ISG15, indicating that regulatory/tolerogenic mechanisms may remain in play. This evidence concerns the gene ISG15 and neoplasm.